Physician profile
David Weir
NPI 1528064441
$6,079.02
in general payments reported to CMS, 2019-2025
19 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $416 · 2021: $1,215 · 2022: $987 · 2023: $571 · 2024: $1,467 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,132.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,105.52 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Revance Therapeutics, INC. | $868.30 | 2024-2025 | Daxxify, Daxi |
| Lundbeck LLC | $454.70 | 2020-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $435.45 | 2019-2025 | Austedo Xr |
| Allergan, INC. | $375.64 | 2020-2022 | |
| Pfizer INC. | $344.56 | 2023-2025 | |
| Amgen INC. | $313.44 | 2019-2022 | |
| Lilly USA, LLC | $295.19 | 2019-2024 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company Ltd. | $260.91 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $236.68 | 2021 | |
| Biogen, INC. | $92.24 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $58.85 | 2021 | |
| Upsher-Smith Laboratories LLC | $55.29 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $48.93 | 2019 | |
| Assertio Therapeutics, INC. | $40.28 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $34.55 | 2025 | Symbravo |
| Currax Pharmaceuticals LLC | $23.42 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.73 | 2025 | Keveyis |
| Impel Pharmaceuticals INC. | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.